An observational study in Cancer, sponsored by Charite University, Berlin, Germany. Recruiting at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.
Sponsored by Charite University, Berlin, Germany · Observational
Non-interventional study to assess the non-inferiority of AI-generated treatment recommendations for precision oncology. Molecular tumor profiles will be assessed by local AI models to identify treatment options. Resulting treatment options will then be compared with actual personalized therapy recommendations.
10,818 studies on the registry are indexed under Neoplasms; 2,324 are open to participants now.
This study's planned enrollment of 191 is close to the median of 200 across 2,638 observational studies indexed under Neoplasms.
Browse Neoplasms studies →Charite University, Berlin, Germany is the lead sponsor of 857 studies on the registry; 129 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients with advanced solid tumors planning to undergo comprehensive molecular tumor testing
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
large language model (non-interventional)
Fraction of all actual positively identified treatment options that the model has correctly identified (Recall)
Sensitivity as measured by retrieved relevant treatment options divided by all relevant treatment options with 1 indicating identification of all relevant treatment options.
Time frame: immediately after the intervention (which is the molecular tumor board MTB; standard-of-care intervention)
Fraction of relevant treatment options among all retrieved treatment options (Precision)
Positive predictive value as measured by retrieved relevant treatment options divided by all identified treatment options with 1 indicating the highest positive predictive value
Time frame: immediately after the intervention (MTB SOC intervention)
Harmonic mean of precision and recall (F1-Score)
Analysis of F1 score as harmonic mean between precision and recall with 0 indicating the lowest and 1 the highest possible score.
Time frame: immediately after the intervention (MTB SOC intervention)
clinical trial identification
Number of correctly identified clinical trials
Time frame: immediately after the intervention (MTB SOC intervention)
time of manual and automatic annotation
Comparison of time spent (in minutes) for manual and automatic molecular tumor result annotation
Time frame: immediately after the intervention (MTB SOC intervention)
therapy implementation
Number of patients receiving recommended therapy and outcome
Time frame: 3 months after MTB (SOC intervention)
Plan to share: Undecided
No publications or documents are linked to this record.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Charite University, Berlin, Germany →